07/06/2026
You said: Gip_1 and cerebral amyloid angiopathyGip_1 and cerebral amyloid angiopathy Glucose-dependent insulinotropic polypeptide (GIP) and Glucagon-like peptide-1 (GLP-1) are gut hormones. In neuroscience, dual GIP/GLP-1 receptor agonists are highly promising emerging therapeutic agents. Because they cross the blood-brain barrier, they are actively being investigated to treat neurodegeneration and brain insulin resistance.Cerebral amyloid angiopathy (CAA) is a cerebrovascular disease defined by the buildup of amyloid-beta (Aβ) proteins in the walls of small brain arteries, which often leads to vessel fragility, microbleeds, and cognitive decline.The GIP and GLP-1 ConnectionNeuroprotection: Dual GIP/GLP-1 agonists stimulate the brain, promote neuron survival, and help maintain synaptic connections.Reducing Amyloid: In preclinical studies on Alzheimer’s disease and vascular dementia, activating both receptors reduces overall amyloid plaque accumulation and lowers pro-inflammatory cytokine levels in the brain.Vascular Health: These agonists mitigate brain insulin resistance (often referred to as 'type 3
